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Alloantigen presentation is an essential process in acute allorejection. In this context, we
speculated on a pathogenic role of cathepsin S (Cat-S), a cysteine protease known
to promote antigenic peptide loading into MHC class II and to activate protease-
activated receptor (PAR)-2 on intrarenal microvascular endothelial and tubular epithelial
cells. Single-cell RNA sequencing and immunostaining of human kidney allografts
confirmed Cat-S expression in intrarenal mononuclear phagocytes. In vitro, Cat-S
inhibition suppressed CD4 + T cell lymphocyte activation in a mixed lymphocyte
assay. In vivo, we employed a mouse model of kidney transplantation that showed
preemptive Cat-S inhibition significantly protected allografts from tubulitis and intimal
arteritis. To determine the contribution of PAR-2 activation, first, Balb/c donor kidneys
were transplanted into Balb/c recipient mice without signs of rejection at day 10. In
contrast, kidneys from C57BL/6J donor mice revealed severe intimal arteritis, tubulitis,
interstitial inflammation, and glomerulitis. Kidneys from Par2-deficient C57BL/6J mice
revealed partial protection from tubulitis and lower intrarenal expression levels for Fasl,
Tnfa, Ccl5, and Ccr5. Together, we conclude that Cat-S and PAR-2 contribute to
immune dysregulation and kidney allograft rejection, possibly involving Cat-S-mediated
activation of PAR-2 on recipient parenchymal cells in the allograft.
Keywords: kidney transplantation, cathepsin S, allorejection, proteinase-activated receptor-2, animal model of
transplantation
INTRODUCTION
Among the different forms of renal replacement, therapy kidney transplantation, when available, is
the preferred option for most patients with end-stage kidney disease (Wolfe et al., 1999; Robinson
et al., 2016). Alloimmunity remains an important factor limiting graft survival, and life-long
treatment with relatively non-specific immunosuppressants has remained the standard of care
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to date for the vast majority of patients (Durrbach et al., 2010).
More selective interference with alloimmunity may broaden the
range of options for those patients facing drug toxicity.
Presentation of alloantigen’s is a central path mechanism
of alloimmunity and involves MHC class II molecules on
professional antigen-presenting cells (Borges et al., 2016; Robson
et al., 2018). Within antigen-presenting cells, the maturation of
MHC class II molecules is tightly regulated, whereby the invariant
chain covers the peptide-binding domain up to when peptide
loading occurs and the molecule is shuttled to the cell surface
(Roche and Frusta, 2015; Robson et al., 2018). Cathepsin (Cat-)
S is one of several proteases that chop the invariant chain in a
stepwise process (Shi et al., 1999; Roche and Frusta, 2015); hence,
Cat-S deficiency or pharmaceutical Cat-S inhibition prevents
MHC class II–mediated (auto)antigen presentation (Rise et al.,
1996, 1998; Dresden et al., 1999; Saugus et al., 2002; Stickle et al.,
2012). Indeed, Cat-S inhibition effectively suppresses the immune
dysregulation in numerous experimental autoimmune diseases
(Saugus et al., 2002; Baugh et al., 2011; Rupanagudi et al., 2015;
Tato et al., 2017).
Beyond its role inside cells, monocytes/macrophages,
neutrophils, and endothelial cells secrete Cat-S in the
extracellular space where it processes several matrix proteins
(Lutgens et al., 2007; Reiser et al., 2010). For example, its
elastase activity contributes to vascular wall degeneration in
atherosclerosis and aortic aneurysm formation (Shi et al., 2003;
Sukhova et al., 2003; Rodgers et al., 2006; Aikawa et al., 2009;
Samokhin et al., 2010; Qin et al., 2012; Figueiredo et al., 2015).
Indeed, increased serum levels of Cat-S are associated with
several cardiovascular risk factors including chronic kidney
disease (Jobs et al., 2011, 2013; Lv et al., 2012). As a new
finding, we and others recently described that Cat-S activates
protease-activated receptor (PAR)-2 on vascular endothelial
cells in a thrombin-like manner (Elmariah et al., 2014; Zhao
et al., 2014; Kumar et al., 2016). Cat-S-driven PAR-2 activation
induced endothelial dysfunction, a central path mechanism in
microvascular complications of diabetic mellitus or systemic
autoimmunity (Kumar et al., 2016; Tato et al., 2017).
As both mechanisms, MHC class II–mediated antigen
presentation and microvascular injury also contribute to
immune dysregulation and allograft dysfunction in solid organ
transplantation, we hypothesized that interfering with either Cat-
S or PAR-2 would attenuate organ injury in a robust model of
allograft rejection. To address this concept, we decided for a
rigorous mouse model of acute kidney allograft rejection without
further immunosuppressive therapy.
MATERIALS AND METHODS
Single-Cell RNA Sequencing of Human
Kidney Biopsies
Tissue Processing
The renal biopsy was minced into small pieces with a razor
blade and incubated at 37◦C in freshly prepared dissociation
buffer containing 0.25% trypsin and 40 U/ml DNase I, filtered
resuspended in buffer (9% OptiPrep). Nuclei from normal human
nephrectomy tissue were isolated with Nuclei EZ Lysis buffer with
protease inhibitor and RNase inhibitor. Samples were cut into
<2-mm pieces, homogenized, and incubated on ice for 5 min
with an additional 2 ml of lysis buffer. The homogenate was
filtered, centrifuged, resuspended in suspension Buffer (1× PBS,
0.07% BSA, 0.1% RNase inhibitor), and counted.
InDrops Single-Cell RNA-Seq
InDrops was performed as described (Klein et al., 2015). In
brief, cells were diluted into 60,000 cells/ml in 9% OptiPrep
buffer. Single-cell encapsulation was carried out using an
inDrops instrument and microfluidic chip manufactured by
1CellBio. In total, 4000 cells were collected. Library preparation
was performed according to the protocol provided by the
manufacturer. Libraries were sequenced by HiSeq 2500 with a
sequencing depth of 50K mapped reads/cell.
10× Single-Nucleus RNA-Seq
RNAs from 6000 single nuclei loaded into one lane of the
10 × Genomics 3-prime V2 platform were encapsulated,
barcoded, and reversed transcribed. The library was sequenced in
HiSeq 2500 with a sequencing depth of 12.5K mapped reads/cell.
Data Preprocessing
We used the inDrops computational pipeline, dropEst (Klein
et al., 2015), to process the single-cell InDrops data. We used
STAR to map the high-quality reads to the human genome
(GRCh38). We next ran the dropEst program to estimate the
accurate molecular counts, which generated a UMI count matrix
for each gene in each cell. We used the zUMIs computational
pipeline to process the single nuclei data according to protocol
(Parekh et al., 2018). In brief, fastq files were filtered for low-
quality barcodes and unique molecular identifier (UMIs). Next,
cDNA reads were mapped to the reference genome using STAR.
Count matrices were generated for exon + intron overlapping
reads. These count matrices were used for downstream analysis.
Unsupervised Clustering and Cell Type Identification
UMI count matrices were loaded into the R package Seurat. For
normalization, the DGE matrix was scaled by total UMI counts,
multiplied by 10,000, and transformed to log space. Only genes
found to be expressed in >10 cells were retained. Cells with
a relatively high percentage of UMIs mapped to mitochondrial
genes (≥0.3) were discarded. Moreover, cells with fewer than 300
or more than 4,000 detected genes were omitted, resulting in
4,487 cells. We also regressed out the variants arising from library
size and percentage of mitochondrial genes using the function
RegressOut in R package Seurat. The highly variable genes were
identified using the function MeanVarPlot with the parameters
x.low.cutoff = 0.0125, x.high.cutoff = 6, and y.cutoff = 1, resulting
in an output of 2,404 highly variable genes. The expression level
of highly variable genes in the cells was scaled and centered along
each gene and was conducted to principal component analysis.
Based on PCElbowPlot and PCHeatmap Seurat function analysis,
we first selected 20 PCs for two-dimensional t-distributed
stochastic neighbor embedding (tSNE), implemented by the
Seurat software with the default parameters. Based on the
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tSNE map, sixteen clusters were identified using the function
FindCluster in Seurat with the resolution parameter set to 0.6.
We applied the same unsupervised clustering analysis on the
single nucleus dataset. After filtering low-quality nuclei, 4,609
nuclei with >400 genes expressed were imported into Seurat for
clustering analysis. In total, we identified 13 cell types in the single
nucleus dataset, which included macrophages and endothelial
cells. Integrated analysis of rejecting and normal human kidney
was performed using the Seurat function IntegrateData.
Immunohistochemistry in Human Renal
Biopsies
Human renal tissue, fixed in formaldehyde and embedded
in paraffin, was selected from the files of the Service of
Pathology, University Hospital Geneva: control normal renal
tissue was obtained from two patients with nephrectomy
performed for neoplasia, involving the possibility of tumor-
related immune exhaustion. Five biopsy specimens were
obtained from renal transplant patients with acute T cell–
mediated rejection. For all biopsy specimens, standard analyses
were performed. Each patient gave informed consent before
enrollment. The institutional ethical committee board approved
the clinical protocol (CEREH number 03-081). The research was
performed according to the Helsinki’s declaration principles. For
immunostaining, serial paraffin sections were stained with the
primary antibodies anti-cathepsin S (monoclonal mouse anti-
human Cat-S, LSBio, Seattle, WA, United States) and anti-CD68
(DakoCytomation, Glostrup, Denmark) or double stained with
anti-cathepsin S and anti-CD68. Counterstaining was performed
using Mayer hematoxylin. Negative controls included the absence
of the primary antibody (not shown).
Bone Marrow–Derived Dendritic Cell
Isolation and Differentiation
For bone marrow–derived dendritic cell (BMDC) preparation,
cells were isolated and cultured according to a standard method
with minor modifications (Han et al., 1999). Briefly, bone marrow
cells were cultured in RPMI 1640 media supplemented with 1%
penicillin and streptomycin, 10% of fetal calf serum (S0115, EMD
Millipore, United States), 20 ng/ml of mouse recombinant IL-
4 and GM-CSF (ImmunoTools, Friesoythe, Germany). At day
8, non-adherent cells were transferred to a fresh plate, primed
by 500 µg/ml lipopolysaccharide (LPS, Sigma) for another 24 h,
and used for MLR. In BMDC stimulation assays, non-adherent
cells were transferred to 12-well plate at 2 × 106/ml at day
8, stimulated with indicated stimuli for 24 h, and analyzed
by flow cytometry.
Mixed Lymphocyte Reaction
For in vitro assessment of allogenic T-cell activation, mixed
lymphocyte reaction (MLR) was set up by incubating T
cell–enriched splenocytes together with bone marrow–derived
dendritic cells (BMDCs). C57BL/6 (H-2b) and Balb/c (H-2d)
mice were used at the age of 7–15 weeks. For T cell preparation,
pan T-cells were enriched from splenocytes by a magnetic bead–
based negative selection method (Mouse Pan T-cell Isolation Kit
II, Miltenyi Biotec, Germany) according to the manufacturer’s
instruction (purity >90%, data not shown). Purified T cells were
labeled with 5 µM carboxyfluorescein succinimidyl ester (CFSE)
dye (CellTraceTM CFSE Cell Proliferation Kit, Invitrogen)
for 5 min according to the manufacturer’s instruction. For
proliferation assay, 1.5 × 105 CFSE-labeled T cells and 1 × 105
of primed BMDCs were cocultured in round bottom 96-well plate
(Nunc, Germany) for 4 days. Mixed cells were afterward analyzed
by flow cytometry to evaluate the proliferation.
Flow Cytometry Analysis
Single-cell suspensions from BMDC stimulation assay or
MLR were washed in cold DPBS (PAN Biotech, Germany)
twice and suspended in cold FACS buffer (DPBS with 1%
BSA and 0.05% sodium azide). Single-cell suspensions were
first treated with anti-mouse CD16/32 antibody (BioLegend,
United States). Cells from BMDC stimulation assay were
stained for anti-mouse CD11c-PE (clone HL3, BioLegend,
United States) and anti-mouse MHCII-FITC (clone M5/114.15.2,
BioLegend, United States). Cells from MLR were stained for
anti-mouse CD8-PE (clone 53-6,7, BioLegend, United States)
and then stained for anti-mouse CD4-APC antibody (RM4-4
clone, BioLegend, United States). Samples were analyzed on
a flow cytometry analyzer (BD FACSCalibur). For analysis of
proliferation, after gating in live/CD4 + CD8- or live/CD4-
CD8 +, CFSE histograms were deconvoluted to differentiate
each daughter generation from parent cells by software (FlowJo,
version 7.6.5) (Supplementary Figure S1A). Division index was
calculated by the ratio of the total number of divisions over the
number of cells at start of culture.
Lactate Dehydrogenase Cytotoxicity
Assay
Lactate dehydrogenase (LDH) cytotoxicity assay was set up by
mixing 1.5 × 105 of CFSE-stained T cells and 1 × 105 of LPS-
primed BMDCs in RPMI 1640 media supplemented with 1%
penicillin and streptomycin and 10% of fetal calf serum. Cells
were incubated for 4 days. At day 4, cell death was evaluated using
LDH cell cytotoxicity assay kit (Roche, Mannheim, Germany)
according to the manufacturer’s protocol.
Animal Study Design
C57BL/6J (H2b) and Balb/c (H2d) mice were obtained from
Charles River (Sulzfeld, Germany) and used at the age
of 8–12 weeks. Par2-/- mice in the C57BL/6J background
were purchased from Jackson Laboratory (Bar Harbor, ME,
United States). Offspring were genotyped by polymerase chain
reaction (PCR) of genomic DNA derived from tail clippings.
Animals were assigned by stratified randomization to different
groups co-housed in groups of five in filter top cages with
unlimited access to food and water. Cages, nestlets, food,
and water were sterilized by autoclaving before use. Humane
endpoints were monitored throughout the study. All experiments
were conducted according to the European equivalent of the
NIH’s Guide for the Care and Use of Laboratory Animals and had
been approved by the local government authorities.
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Kidney transplantations were performed as previously
described (Skoskiewicz et al., 1973). Following a midline
abdominal incision, the left kidney, aorta, and inferior vena
cava of the donor were fully exposed and mobilized. The kidney
was procured en bloc including the renal vein; the renal artery,
along with a small aortic cuff; and the ureter. The vessels
of the graft were anastomosed end-to-side to the recipient’s
abdominal aorta and inferior vena cava using 10-0 nylon sutures
(AROSurgical, Newport Beach, CA, United States). For urinary
tract reconstruction, the ureter was directly anastomosed into
the bladder using a pull-through (Han et al., 1999). The times
of cold and warm ischemia of the graft were maintained at 40
and 30 min, respectively. The native kidneys of the recipient
remained untouched as this was a non-life-sustaining approach.
Primary Endpoint: Harvested allografts were split in half and
either paraffin embedded or snap frozen and kept at −80◦C.
Light microscopy was performed on HE- and PAS-stained whole
cross sections of kidney allografts. An experienced blinded
nephropathologist (S. M.) evaluated and scored for tubulitis,
intimal arteritis, interstitial inflammation, and glomerulitis as
well as periarteritis using a 4-point-score (0–3) and assigned a
score according to the Banff criteria (Haas et al., 2014).
Secondary Endpoints: Real-time reverse transcription-
polymerase chain reaction (RT-PCR). Gene expression was
assessed by real-time quantitative RT-PCR as described
(Lech et al., 2010). In brief, total RNA was isolated using
an RNA extraction kit (Life Technologies, Darmstadt,
Germany) according to the manufacturer’s instructions.
After isolation of RNA, cDNA was generated using reverse
transcriptase (Superscript II; Invitrogen, Carlsbad, CA,
United States). A SYBR Green Dye detection system was
used for quantitative real-time PCR on Light Cycler 480 (Roche,
Mannheim, Germany) using SYBR Green (SABiosciences)
as marker and 18s rRNA as a housekeeping gene. Gene-
specific primers blasted with ensemble-BLAST and NCBI
primer-BLAST (Metabion, Martinsried, Germany) were
used. The following are forward and reverse gene-specific
primers, respectively (300 nM; Metabion, Martinsried,
Germany): 18s, GCAATTATTCCCCATGAACG and AGG
GCCTCACTAAACCATCC; Ifng, TGAGCTCATTGAATGCTT
GG and ACAGCAAGGCGAAAAAGGAT; Fasl, TTAAATGGG
CCACACTCCTC and ACTCCGTGAGTTCACCAACC; Ctss,
GAGTCCCATAGCCAACCACAAG and AAGCGGTGTCTATG
ACGACCC; and Ccl5, GTGCCCACGTCAAGGAGTAT and
CCACTTCTTCTCTGGGTTGG; Ccr5, GTCTACTTTCTCTT
CTGGACTCC and CCAAGAGTCTCTGTTGCCTGCA; Foxp3,
CTGGACACCCATTCCAGACT and TTCATGCATCAGCTC
TCCAC; Il2ra, GCGTTGCTTAGGAAACTCCTGG and GCATA
GACTGTGTTGGCTTCTGC, Cd8b1, GAATGTGAAGCCAGA
GGACAGTG and GGGCAGTTGTAGGAAGGACATC; Cd4,
GTTCAGGACAGCGACTTCTGGA and GAAGGAGAACTCC
GCTGACTCT. Non-template controls consisting of all used
reagents were negative for target and housekeeping genes.
To reduce the risk of false-positive crossing point, the high-
confidence algorithm was used. The melting curve profiles were
analyzed for every sample to detect eventual unspecific products
or primer dimers.
Histology was a secondary endpoint. Kidneys were fixed
in 4% formalin, embedded in paraffin. Immunostaining was
performed as described using anti-mouse MHC-II (1:100, clone
M5/114.15.2, eBioscience, United States) (Kumar et al., 2016).
Statistical Analysis
Normal data distribution was tested using the Shapiro–Wilk
test. Comparisons between two groups were performed with
Student’s t-test or Mann–Whitney U test. Comparison of
multiple groups was performed with ANOVA or Kruskal–Wallis
test; a multiple comparison test was performed with Dunnett
or Dunn’s correction, respectively. A value of p < 0.05 was
considered to indicate statistical significance. Data are presented
as mean± SD.
RESULTS
Cathepsin S–Positive Cells Accumulate
in Rejecting Human Kidney Allografts
We compared single-cell Cat-S expression (CTSS) in human
kidney allograft with mixed rejection and normal human kidney
(Wu et al., 2018). Integrated analysis of rejecting and normal
human kidney identified 16-cell clusters including all major
tubular and immune cell types and endothelial cells (Figure 1A).
Compared to normal kidney, high expression of CTSS is seen in
macrophages and intercalated cells (Figures 1B upper, 1C left).
To confirm these data, we performed immunostaining in biopsies
from transplanted patients diagnosed with kidney allograft
rejection, as well as biopsies from healthy controls. As shown in
Figure 2A, Cat-S-positive cells were sparse in the interstitium of
healthy kidneys and were most likely expressed by CD68 + cells.
In contrast, we found numerous CD68/Cat-S double-positive
cells accumulating in rejected allografts (Figure 2B). Together,
Cat-S was strongly expressed inside human kidney allografts.
Cathepsin S Inhibition Suppresses
Alloimmune Lymphocyte Proliferation
in vitro
As Cat-S is a non-redundant component in MHC class II–
driven antigen presentation, it should also drive MHC class
II–related alloantigen presentation and alloimmunity. We tested
this concept by performing mixed lymphocyte assays (Figure 3A)
and measured CD4 + T lymphocyte division as a readout
for alloantigen-specific lymphocyte activation. As shown in
Figure 3B, Cat-S inhibition did not significantly affect BMDC
MHC class II expression. In MLR, however, Cat-S inhibitor–
treated groups had less proportion of divided CD4 + T cells
(Figure 3C). Quantification of the division index also showed that
the Cat-S inhibitor suppressed CD4 + T cell and CD8 + T cell
division in a dose-dependent manner (Figures 3D,E). This effect
was independent of cytotoxicity of the Cat-S inhibitor as LDH
release was identical in all groups (Figure 3F). Thus, we conclude
that Cat-S inhibition blocks alloimmune CD4 + and CD8 + T
lymphocyte proliferation in vitro.
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FIGURE 1 | Cat-S and PAR-2 gene expression in healthy and rejected human kidney biopsies by single-cell RNA-seq. (A) UMAP plots of combined correlation
analysis of a mixed rejection kidney transplant biopsy and a healthy human kidney tissue sample. Left: cell clusters labeled by cell type. Right: clusters labeled
according to rejection (blue) or healthy (red) kidney. (B) Violin plots of Cat-S (CTSS) and PAR-2 (F2RL1) gene expression per cell type, in rejection (green) and healthy
(red). Upper: CTSS expression. Lower: F2RL1 expression. (C) Feature UMAP plots of Cat-S (left) and PAR2 (right) expression. Purple color demotes high gene
expression.
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FIGURE 2 | Cat-S expression in kidney biopsies from renal transplant patients with acute T cell–mediated rejection by immunostaining. (A) Cat-S and CD68 staining
in health human kidney tissue. Consecutive kidney slides were stained for CD68 (left, in red) and Cat-S (right, in brown). CD68-positive cells and Cat-S-positive cells
were marked by black arrows. Magnification 200×. (B) Cat-S and CD68 staining in rejecting human kidney allografts. CD68 single staining (left), Cat-S single
staining (middle), and Cat-S/CD68 double staining (right) was performed on tissues from patients undergoing kidney rejection. Cat-S/CD68 double-positive cells
were marked by black arrow.
Preemptive Cathepsin S Inhibition
Attenuates Acute Kidney Allograft
Rejection
Based on these findings, we tested whether Cat-S inhibition
can attenuate kidney allograft rejection in vivo. We set up
an experimental model based on C57BL/6J (H2b)–recipient
mice (Figure 4A). We investigated the Cat-S expression in
transplanted kidneys. Compared to syngeneic controls, allograft
showed numerous Cat-S-positive cells accumulating in the
interstitium, especially around vessels (Figure 4B). Likewise,
Cat-S gene expression was also significantly induced in allograft
(Figure 4C). Transplanting a kidney from a donor of the same
strain showed minimal differences in the histological picture
compared to the native kidneys 10 days after the surgery,
implying that the transplant procedure per se was reliably
performed and did not cause tissue damage by ischemia–
reperfusion injury (Figure 4D). In contrast, kidneys from Balb/c
(H2d) donor mice showed signs of severe rejection with tubulitis,
glomerulitis, intimal arteritis, and interstitial inflammation
(Figure 4D). Treating recipient mice with the Cat-S inhibitor
RO5461111 completely abrogated tubulitis, intimal arteritis, but
not glomerulitis and interstitial inflammation (Figure 4D). As a
further sign of intrarenal inflammation, quantitative RT-PCR of
total kidney RNA revealed increased levels of proinflammatory
mediators such as Ccl5, Ccr5, Fasl, and Ifng (Figure 4E). Cat-S
inhibition reduced intrarenal expression levels of above genes.
Cat-S inhibition also reduced Cd4 and Cd8b1 gene expression
(Figure 4F). However, it did not affect Foxp3 or Il2ra gene
expression (Supplementary Figure S1B). The Cat-S inhibitor
also did not affect MHC class II expression in graft (Figure 4G
and Supplementary Figure S1D). Cat-S inhibition reduced
intrarenal expression levels of the above genes (Figure 4E).
Taken together, Cat-S inhibition substantially attenuates kidney
allograft rejection.
Lack of Par2 in the Kidney Allograft
Attenuates Acute Rejection in Recipient
Balb/c Mice
PAR-2 is a G protein receptor and acts as the receptor for
many extracellular enzymes, such as Cat-S, trypsin, and tryptase.
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FIGURE 3 | Effect of Cat-S inhibitor on MLR and cytotoxicity. (A) Experiment design of mixed lymphocyte reaction for proliferation and LDH assay. LPS-primed
BMDCs (Balb/c) and CFSE-stained T cells (C57BL/6J) were used as stimulator and responder, respectively. Mixed cells were cocultured for 4 days and analyzed by
flow cytometry or LDH assay. (B) BMDC stimulation assays. BMDCs were stimulated with 500 ng/ml LPS, Cat-S inhibitor, or vehicle for 24 h and analyzed for
MHC-II expression among CD11c + cells. (C) CD4 + T cell proliferation monitored using CFSE labeling. Mixed cells were in the presence of 0.2, 2, 20 µg/ml, or
vehicle, and proliferation was analyzed by flow cytometry at 4 days of culture. As controls, mixed cells with no CFSE were treated as the same way as vehicle but
without CFSE staining; single T cells were treated with vehicle but without adding BMDCs. After gating in CD4 + cells, divided cells were gated in the histograms of
the CFSE channel. A representative experiment from two separate experiments is shown. For each experiment, one mouse was used for BMDC differentiation and
two mice were used for T cell isolation. Two or three replications was made from each T cell host for MLR. (D) Division index of CD4 + T cells. Based on the
deconvoluted histograms of the CFSE channel, the division index was calculated by the ratio of the total number of divisions over the number of cells at start of
culture. (E) The division index of CD8 + T cells. (F) LDH assay for Cat-s inhibitor–treated cells. Supernatant of mixed cell culture was analyzed at day 4 by LDH.
*p < 0.05, **p < 0.01, ****p < 0.0001.
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FIGURE 4 | Cathepsin S inhibition attenuated renal allograft rejection in vivo. (A) Experimental design. Wild-type C57BL/6 kidneys (syngeneic) or wild-type Balb/c
kidneys (allogeneic) were transplanted into wild-type C57BL/6 mice. Allogenic recipients were orally administrated with either vehicle or Cat-S inhibitor 10 mg/kg
twice daily for a total of 11 days. At day 10 after transplantation, mice were analyzed. (B) Cat-S staining in mouse kidney grafts from syngeneic (B6 to B6) and
allogeneic group (Balb/c to B6). White dash lines represent for vessels. Magnification 200×. (C) Ctss mRNA expression in mouse kidney grafts. (D) Histological
score for mouse kidney grafts. Tubulitis, intimal arteritis, glomerulitis, and interstitial inflammation were quantified by Banff scoring method. ***p < 0.001 Balb/c to B6
vs. B6 to B6; ****p < 0.0001 Balb/c to B6 vs. B6 to B6; ##p < 0.01 Balb/c to B6 vs. Balb/c to B6 + Cat-S inhibitor. N = 10 for B6 to B6, n = 9–10 for Balb/c to B6,
n = 8–10 for Balb/c to B6 + Cat-S inhibitor. (E) Proinflammation gene expression in mouse kidney grafts by RT-qPCR. (F) Cd4 and Cd8b1 gene expression in mouse
kidney grafts. (G) Quantification of interstitial MHC-II positive cells in mouse kidney graft. *p < 0.05; **p < 0.01; ***p < 0.001. B6 represents for C56BL/6J.
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FIGURE 5 | Par2 deficiency in grafts attenuated renal allograft rejection in vivo. (A) Experimental design. Wild-type Balb/c kidneys (syngeneic) or wild-type C57BL/6
(allogeneic) were transplanted to wild-type Balb/c mice. Par2-deficient kidneys from C67BL/6 background (allogeneic) were transplanted into wild-type Balb/c mice.
At day 10 after transplantation, mice were sacrificed for analysis. (B) Histological score for mouse kidney grafts. Tubulitis, intimal arteritis, glomerulitis, and interstitial
inflammation were quantified by the Banff scoring method. **p < 0.01 B6 to Balb/c vs. Balb/c to Balb/c, ***p < 0.001 B6 to Balb/c vs. Balb/c to Balb/c, #p < 0.05
B6 to Balb/c vs. Par2KO to Balb/c. N = 4 for Balb/c to Balb/c, n = 4–6 for B6 to Balb/c, n = 6 for Par2KO to Balb/c. (C) Proinflammation gene expression in mouse
kidney grafts by RT-qPCR. (D) Cd4 and Cd8b1 gene expression in mouse kidney grafts. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. B6 represents for
C56BL/6J. Par2KO represent for Par2 deficiency.
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The Cat-S/PAR-2 axis was previously reported to play a role
in itch, pain, and diabetic microvasculopathy (Kumar et al.,
2016; Zhao et al., 2014; Mihara et al., 2016). Interestingly,
using single-cell sequencing data of human kidney allograft
rejection, we found F2RL1, the human gene encoding for PAR-
2 to be expressed at low levels by several renal parenchymal
cell types including endothelial cells and tubular epithelial cells
(Figures 1B lower, 1C right). We therefore asked whether
PAR-2 also plays a role in this setting. We designed the
animal experiment as shown in Figure 5A. Compared to
kidneys from wild-type B6 donors, kidneys from Par2-deficient
donor mice showed significantly less tubulitis, non-significant
trends toward less glomerulitis, and less intimal arteritis, and
no effect on interstitial inflammation (Figure 5B). However,
Par2-deficient allografts also showed reduced expression of the
inflammatory genes Ccl5, Ccr5, Fasl, and Ifng (Figure 5C). In
contrast to mice treated with Cat-S inhibitor, Par2-deficient
allografts did not show reduced mRNA expression of Cd4 and
Cd8b1 (Figure 5D) and of Foxp3 and Il-2ra (Supplementary
Figure S1C). Together, donor Par2 deficiency attenuates acute
allograft rejection.
DISCUSSION
We had hypothesized that interfering with either Cat-S or
PAR-2 would attenuate kidney injury in a robust model
of renal allograft rejection. We tested this concept using a
pharmacological inhibitor of Cat-S and genetic Par2 deficiency
in different versions of the same kidney transplant model in
mice based on the two strains C57Bl/6J (H2b) and Balb/c
(H2d). By avoiding additional immunosuppressive therapy,
we tested the role of these targets in severe acute rejection.
The results confirm the hypothesis and identify Cat-S/PAR-
2 as potential molecular targets in the context of solid
organ transplantation.
Alloantigen recognition is a central path mechanism of
alloimmunity. Both donor- and recipient-derived antigen-
presenting cells activate recipient alloreactive T cells to proliferate
and circulate, a process leading to alloantigen recognition
inside the graft and local alloimmunity, i.e., rejection. These
processes involve both MHC class I and II molecules of which
peptide loading into MHC class II but not class I molecules is
controlled by Cat-S (Rise et al., 1996). In support of this concept,
Cat-S inhibition suppressed lymphocyte proliferation in a mixed
lymphocyte assay, an accepted in vitro model of alloantigen
recognition (Ansari and Strom, 2010). Our in vivo data further
demonstrate that preemptive Cat-S inhibition was sufficient to
suppress some aspects of acute renal allograft rejection, namely,
tubulitis and arteritis, while, e.g., interstitial inflammation was
hardly affected. This may relate to the contribution of MHC
class I–mediated alloantigen recognition, and this suggests that
monotherapy with a Cat-S inhibitor may be insufficient to control
allograft rejection. In this regard, alloimmunity significantly
differs from autoimmunity, which can be well controlled
by Cat-S inhibitor monotherapy (Rupanagudi et al., 2015;
Tato et al., 2017).
However, we and others have previously shown that
Cat-S inhibition also prevents Cat-S-mediated activation of
PAR-2 on vascular endothelial cells and thereby attenuates
endothelial dysfunction–related organ injury (Kumar et al.,
2016). In the setting of kidney transplantation, this would
imply a potential dual renoprotective effect of Cat-S inhibition,
one on alloantigen recognition and one of microvascular
injury in the allograft. Indeed, our data show a considerable
renoprotective effect of genetic Par2 deficiency in the allograft.
This genetic approach overcomes some of the concerns
related to small molecule inhibitors such as exposure, dosing,
dosing intervals, and specificity. Nevertheless, we found
similar renoprotective effects as compared to the Cat-S
inhibitor, indicating that the renoprotective effects of the
Cat-S inhibitor largely relate to its activity at PAR-2. However,
Par2 deficiency also abrogates the activity of other serum
proteases such as thrombin, which can have similar biological
effects (Mihara et al., 2016). Although specific targeting of
PAR-2 with drugs would be feasible, in the setting of solid
organ transplantation targeting the dual activity of Cat-S
appears more promising, potentially in combination with
an immunosuppressive drug that also controls MHC class
I–mediated alloimmunity.
Obviously, our study presents with some limitations. First,
we could not ultimately prove that the Par2-dependent
effects relate to Cat-S activity. Also, other proteases such
as thrombin induce PAR-2 signaling on endothelium and
tubular epithelial cells (Vesey et al., 2013; Mihara et al.,
2016). Second, because of the robust nature of the acute
rejection, it was difficult to quantify immune cell infiltrates
and endothelial integrity properly and the life-non-sustaining
transplantation technique did not allow testing for renal
function. Finally, it would have been desirable to validate
the experiments with Cats-deficient mice but such mice
fulfilling the microbial requirements of our animal facility could
not be obtained.
Together, Cat-S and PAR-2 are potential molecular targets in
acute renal allograft rejection. Further studies will evaluate its
potential in models that mimic more closely the clinical scenario
of acute (and chronic) human allograft rejection.
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FIGURE S1 | (A) Gating strategy for proliferation analysis of mixed lymphocyte
reaction. (B) Foxp3 and Il2ra gene expression in mouse kidney grafts from mice
treated with Cat-S inhibitor or vehicle. (C) Foxp3 and Il2ra gene expression in
mouse kidney grafts from wild type or Par2 deficient mice. (D) Representative
images of MHC-II staining in mouse kidney grafts treated with Cat-S inhibitor or
vehicle. Magnification, 200×.
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